Affiliated with Emory University SOM Division of Vascular Surgery and Atlanta Veteran Affairs Medical Center. Focus on advanced limb reconstruction procedures after amputation and large-animal (swine) models of peripheral arterial disease. Responsibilities include both basic and clinical research: grant and manuscript preparation; Clinical Trial support; lab manager; liaison to IACUC/DAR; Animal surgery; husbandry; tissue preparation / histology; database management

Coté Orphan, LLC, a regulatory affairs advisory firm based in Silver Spring, MD, provides valuable strategic planning and execution services to companies developing or seeking to develop orphan drugs. Under the leadership of Dr. Timothy R. Coté, an orphanology expert and former Food and Drug Administration (FDA) Director for the Office of Orphan Products Development (OOPD), Coté Orphan demystifies the FDA regulatory process. Coté Orphan knows the FDA hurdles unique to orphan products and forges successful pathways to regulatory success.Orphan drugs are the most exciting opportunity in drug development. Today nearly 40% of all new product market approvals the FDA grants are for orphan products. Orphan drug development is different; it involves special regulatory affairs, special drugs, special financial metrics, and special science. Unique experience is required to work with orphan drugs, experience not usually found amongst those who traditionally develop drugs for common diseases. Now your company has the opportunity to harness this special knowledge with unparalleled expert training from an insider, the industry leader in “orphanology”, former FDA Director of the Office of Orphan Product Development, Dr. Timothy R. Coté.Contact InformationCoté Orphan, LLC8630 Fenton Street, Suite 724Silver Spring, MD 20910US: 202.779.9599UK: 44.203.514.3684Fax: 202.318.5386Email: info@coteorphan.com

• Served as Accountant and Internal Auditor for Dartmouth student-run custom apparel company• The company grossed over $100,000 of revenue in 2012, with $25,573.81 in net income• Oversaw transition from a C-Corp to an S-Corp to attain tax-exempt status and maximize after-tax income• Revenue and Net Income outperformed expectations by over 20% in 2012, growing by 80% between 2011 and 2012• Cultivated customer-focused relationships with clients, vendors, and printers to ensure timely inventory delivery, maximize client satisfaction and optimize market profitability

Contributed to clinical research projects assessing the Quality of Life of Dr. Gedge D. Rosson’s plastic surgery patients who underwent mastectomy and reconstruction proceduresCo-authored an abstract from a systematic review and meta-analysis of the BREAST-Q, a patient reported outcome (PRO) instrument. The abstract has been submitted to a national meeting in ChicagoCollaborated with research fellows on collective projects and led presentations on team research progress

• Aided in laboratory research on a prostate cancer pro-drug derived from the toxin Thapsigargin• Maintained 6 cancer cell-line cultures under Dr. John Isaacs at JHMI as part of experiment on PSMA expression • Observed and conducted multiple different protein analysis assays • Evaluated samples under microscope and recorded changes• Took measurements of mouse-model tumors to test drug efficacy

• Encouraged player development of 30 boys ages 14-15 by tailoring my motivation techniques to suit each player’s learning style and skill level• Entrusted to direct drills without supervision from the head coach that covered team strategy, individual technique, and game-time scenarios; adjusted use of personnel and strategy to increase team success